viagenpumatucel l

Drug Overview

viagenpumatucel l is a groundbreaking, experimental treatment that falls into the category of Immunotherapy. It is designed to act as a therapeutic cancer vaccine. Instead of trying to prevent cancer like a traditional vaccine prevents the flu, this “Smart Drug” trains the patient’s own body to recognize and fight cancer that is already there.

• Generic Name: Viagenpumatucel-L (often referred to in clinical trials as HS-110).
• US Brand Names: None (Currently an Investigational Drug).
• Drug Class: Allogeneic Cellular Vaccine; Immunotherapy.
• Route of Administration: Intradermal injection (a small shot given just under the skin).
• FDA Approval Status: Investigational. It is currently being studied in late-stage clinical trials and is not yet approved by the FDA for the general public.

What Is It and How Does It Work? (Mechanism of Action)

Viagenpumatucel-L is an “off-the-shelf” cellular therapy. It is made from a human lung cancer cell line that has been safely modified in a laboratory.

The Training Camp: gp96 Protein

To understand how it works, think of the immune system as an army. Cancer cells are good at hiding from this army. At the molecular level, viagenpumatucel-L cells are engineered to produce high amounts of a special “chaperone” protein called gp96.

Molecular Signaling and Immune Activation

1. The Delivery: When the vaccine is injected under the skin, the modified cells release the gp96 protein. Attached to this protein are multiple cancer testis antigens (tiny protein pieces or “ID tags” that belong to the cancer).
2. The Scouts: The body’s “scout cells” (called Antigen-Presenting Cells or dendritic cells) spot the gp96 protein. They absorb the protein and the attached cancer ID tags through specific receptors (like Toll-like receptor 4).
3. The Attack: The scout cells travel to the lymph nodes and show these cancer ID tags to the immune system’s heavy soldiers (CD8+ killer T-cells). This powerful signaling pathway fully activates the T-cells, sending them into the bloodstream to hunt down and destroy any lung cancer cells wearing those specific ID tags.

FDA Approved Clinical Indications

Because viagenpumatucel-L is an investigational drug, it does not currently have standard FDA-approved uses. It is only available to patients who are taking part in controlled clinical trials.

• Oncological Uses (In Clinical Trials):
  • Advanced Non-Small Cell Lung Cancer (NSCLC). It is heavily studied in patients who have already tried other treatments.
• Non-oncological Uses:
  • None at this time.

Dosage and Administration Protocols

Because it is an experimental cellular vaccine, it is not given through a long IV drip like chemotherapy. It is given as a quick injection into the skin.

Dose Adjustments:

• Renal/Hepatic Insufficiency: Unlike chemical drugs that must be filtered out by the liver or kidneys, viagenpumatucel-L is processed entirely by the local immune system in the skin and lymph nodes. Because of this, dose adjustments for patients with mild to moderate kidney or liver problems are generally not required.

Clinical Efficacy and Research Results

Recent clinical trial data (specifically from the DURGA Phase 2 trial updated between 2020 and 2024) has shown very promising results when viagenpumatucel-L is combined with another immunotherapy drug called nivolumab.

• Survival in New Patients: For patients with advanced lung cancer who had never taken an immune checkpoint inhibitor before, the combination therapy resulted in a median Overall Survival (OS) of 24.6 months. This is highly favorable, as the 1-year survival rate reached 61.7%.
• Survival in Previously Treated Patients: For patients whose cancer had already outsmarted other immunotherapy drugs, the median Overall Survival was 11.9 months. This offers significant hope, as historical data shows standard chemotherapy in this situation usually only provides 6.8 to 9.0 months of survival.
• A Unique Sign of Success: Researchers found a fascinating numerical link: patients who developed a visible “Injection Site Reaction” (redness or swelling where the shot was given) actually had significantly longer survival times. The reaction proved the immune system was actively waking up to fight the cancer.

Safety Profile and Side Effects

One of the greatest benefits of viagenpumatucel-L is that it is generally very well tolerated, especially compared to harsh chemical therapies.

Important Safety Note: As an investigational drug, there is no official FDA “Black Box Warning.” The drug is considered highly safe in trials so far, with very few patients having to stop treatment due to side effects.

Common Side Effects (>10%)

• Injection Site Reactions (ISR): Redness, swelling, or itching where the shot is given. (Remember, this is often a good sign that the drug is working!)
• Fatigue: Feeling unusually tired.
• Skin Rash: A mild, spotty rash (maculopapular rash).
• Nausea and Diarrhea: Mild upset stomach.

Serious Adverse Events

• In the Phase 2 clinical trials, there were no treatment-related serious adverse events directly linked to viagenpumatucel-L. However, because it is given with other strong immune drugs (like nivolumab), patients are monitored for overactive immune responses that can cause inflammation in the lungs or bowels.

Management Strategies

• Let the Reaction Happen: If you get redness at the injection site, do not apply anti-itch creams or steroids unless your doctor tells you to. You want your immune system to react to the spot.
• Rest: Manage fatigue by taking short naps and conserving energy on injection days.

Connection to Stem Cell and Regenerative Medicine

Viagenpumatucel-L is deeply connected to the expanding field of Cellular Therapy and Immunotherapy. Current clinical research is heavily focused on combining this cellular vaccine with other immune-boosting drugs (like PD-1 inhibitors). The goal of this combination is regenerative: while the vaccine acts as the “ignition” to start a massive T-cell response, the other immunotherapy drugs act as the “fuel” to keep those cells fighting. Scientists are studying how this cellular approach can generate long-lasting “memory” T-cells, effectively regenerating a healthy, cancer-fighting immune environment that protects the patient for years after the treatment ends.

Patient Management and Practical Recommendations

Pre-treatment Tests

• Biomarker Testing: A biopsy to check your tumor’s PD-L1 expression and Tumor Mutational Burden (TMB) to see how well your immune system might respond.
• Basic Blood Panels: To ensure your white blood cells are healthy enough to be “trained” by the vaccine.

Precautions During Treatment

• Avoid Immune Suppressants: Do not take high doses of corticosteroid pills (like prednisone) unless absolutely necessary, as they can put your immune system to sleep and stop the vaccine from working.
• Watch for Fever: A low-grade fever can be a normal sign of your immune system waking up, but always report it to your doctor to rule out an infection.

“Do’s and Don’ts” List

• DO show up for all your weekly injection appointments. The training of your immune system requires consistency.
• DO tell your doctor immediately if you develop a severe cough or shortness of breath (a potential side effect of the other immunotherapy drugs used with the vaccine).
• DON’T scratch or rub the injection site aggressively, even if it becomes itchy or red.
• DON’T receive any live vaccines (like the nasal flu spray or yellow fever vaccine) without clearing it with your oncologist first.

Legal Disclaimer

The information in this guide is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Viagenpumatucel-L is an investigational medication and is only available to patients participating in approved clinical trials. Always consult your oncologist or licensed healthcare provider regarding your specific medical condition, trial eligibility, and treatment options. Individual results and side effects from clinical trials may vary.